Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …

Cost-efficacy of currently applied treatments is an issue in overall cancer management
challenging healthcare and causing tremendous economic burden to societies around the …

The capacity of targeted anticancer agents to exert immunomodulatory effects provides a
strong rationale to develop novel agents suitable for combinatorial regimens with …

Simple Summary Immune checkpoint inhibitors (ICIs) are the most mature treatment of
immunotherapy and have changed the mode of cancer treatment. Recent studies showed …

Despite the remarkable successes of cancer immunotherapies, the majority of patients will
experience only partial response followed by relapse of resistant tumors. While treatment …

Background High expression of immune checkpoints in tumor microenvironment plays
significant roles in inhibiting anti-tumor immunity, which is associated with poor prognosis …

Simple Summary Immunotherapies and molecularly targeted therapies have drastically
changed the therapeutic approach for unresectable advanced or metastatic melanoma. The …

Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …

The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in
mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet …

The recent development of high-throughput genomics has revolutionized personalized
medicine by identifying key pathways and molecular targets controlling tumor progression …